Agenus Inc. (AGEN)

Price$3.48

Value ScoreB

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-34.35%

Price vs S&P 500 (4W)-13.83%

VGM Score64.39

Market Capitalization$144.08M

P/E Ratio (Annual)1252.89x

All Metrics

Book Value / Share (Quarterly)$0.24

P/TBV (Annual)31.87x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.22%

Cash Flow / Share (Quarterly)$-2.27

Price vs S&P 500 (YTD)0.53%

Gross Margin (TTM)99.29%

Net Profit Margin (TTM)52.16%

EPS (TTM)$1.67

10-Day Avg Trading Volume0.65M

EPS Excl Extra (TTM)$1.67

Revenue Growth (5Y)5.31%

EPS (Annual)$0.00

ROI (Annual)-49.19%

Gross Margin (Annual)99.11%

Net Profit Margin (5Y Avg)-121.87%

Cash / Share (Quarterly)$0.91

P/E Basic Excl Extra (TTM)2.23x

Revenue Growth QoQ (YoY)40.18%

P/E Normalized (Annual)1252.89x

ROA (Last FY)0.05%

Revenue Growth TTM (YoY)24.46%

EBITD / Share (TTM)$3.48

ROE (5Y Avg)-132.67%

Operating Margin (TTM)87.93%

Cash Flow / Share (Annual)$-2.19

P/B Ratio42.18x

P/B Ratio (Quarterly)153.49x

Net Income / Employee (Annual)$1,400

EV / Revenue (TTM)3.25x

Net Interest Coverage (TTM)0.96x

ROA (TTM)31.05%

EV / EBITDA (TTM)3.46x

EPS Incl Extra (Annual)$0.00

Current Ratio (Annual)0.41x

Quick Ratio (Quarterly)0.37x

3-Month Avg Trading Volume0.72M

52-Week Price Return9.38%

P/E Incl Extra (TTM)2.23x

Revenue / Employee (TTM)$1,529,200

Tangible BV / Share (Quarterly)$0.60

P/S Ratio (Annual)1.26x

Asset Turnover (Annual)0.50x

52-Week High$7.34

Operating Margin (5Y Avg)-64.44%

EPS Excl Extra (Annual)$0.00

CapEx CAGR (5Y)-71.97%

Tangible BV CAGR (5Y)-23.22%

26-Week Price Return-18.41%

Quick Ratio (Annual)0.41x

13-Week Price Return4.17%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)0.38x

Enterprise Value$402.67M

Revenue / Share Growth (5Y)-17.78%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)-61.57%

Revenue / Employee (Annual)$1,409,800

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-2.70%

Cash / Share (Annual)$0.08

3-Month Return Std Dev97.41%

Gross Margin (5Y Avg)96.94%

Net Income / Employee (TTM)$797,600

ROE (Last FY)-69.47%

Net Interest Coverage (Annual)1.74x

EPS Basic Excl Extra (Annual)$0.00

P/FCF (TTM)1.32x

Receivables Turnover (TTM)35.82x

Total Debt / Equity (Quarterly)4.01x

EPS Incl Extra (TTM)$1.67

Receivables Turnover (Annual)102.05x

ROI (TTM)48.69%

P/S Ratio (TTM)1.16x

Pretax Margin (5Y Avg)-127.38%

Revenue / Share (Annual)$3.84

Tangible BV / Share (Annual)$2.02

Forward P/E5.29x

Price vs S&P 500 (52W)-18.83%

P/E Ratio (TTM)2.23x

Year-to-Date Return11.46%

5-Day Price Return12.54%

EPS Normalized (Annual)$0.00

ROA (5Y Avg)-47.40%

Net Profit Margin (Annual)0.10%

Month-to-Date Return-10.49%

Cash Flow / Share (TTM)$-0.81

EBITD / Share (Annual)$3.05

Operating Margin (Annual)70.54%

LT Debt / Equity (Annual)0.37x

ROI (5Y Avg)-75.46%

P/E Excl Extra (TTM)2.23x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$1.67

P/TBV (Quarterly)79.78x

P/B Ratio (Annual)24.02x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)50.45%

Book Value / Share (Annual)$2.68

Price vs S&P 500 (13W)-5.58%

Beta1.55x

P/FCF (Annual)158.33x

Revenue / Share (TTM)$3.24

ROE (TTM)76.63%

52-Week Low$2.71

vGradeB

gGradeB

mGradeC

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.00est. 2.14

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

4.13

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
AGENAgenus Inc.	B	B	C	$3.48
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Agenus is a clinical-stage immunotherapy company developing therapies to activate the immune system against cancer and infectious disease. Its pipeline includes immune-modulatory antibodies (botensilimab, a CTLA-4 inhibitor; balstilimab, a PD-1 inhibitor), adoptive cell therapies through subsidiary MiNK Therapeutics, and vaccine adjuvants via subsidiary SaponiQx. The company operates in-house cGMP manufacturing and clinical operations capabilities to support product development.